PRF Technologies Ltd. is a US-listed company in the pharmaceuticals industry. Its financial year ends in December.
Stock price today
Loading chart…
Third-party market data · may be delayed
Model estimate per share
Not valued: the figures our models need are missing or failed our data-quality checks.
Price vs value
No model value: cash-flow, stock-pay or share-count figures missing or out of date. How we value companies.
PRF Technologies Ltd. valuation: adjust assumptions and compare models →
The Fundamentalytics view
Where it lags: gross margin of -311.8% ranks 59 of 59 pharmaceuticals companies we cover.
Current signal Share count rising (dilution): Diluted shares outstanding rose 368.7% year over year.
Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.
Highlights
How we pick theseStrengths
- Net cash. Cash exceeds long-term debt by $0.0bn.
Things to watch
- Loss-making. Operating margin is -30129.4%: costs exceed revenue.
- Burning cash. Free cash flow was -23276.5% of revenue over the last 12 months.
- Heavy stock-based pay. Stock pay equals 2629.4% of revenue, against a median of 3.6% for pharmaceuticals companies we cover: a real cost that cash-flow figures leave out.
- Share dilution. Diluted shares rose 368.7% in a year.
- Volatile shares. Over the past year the shares showed annualised volatility of 179% and a beta of 2.8 against the S&P 500.
- Below peers: gross margin. Gross margin of -311.8% ranks 59 of 59 pharmaceuticals companies we cover (median 59.8%).
Latest results
- Earnings per share
- -$48.00 against an average estimate of -$124.80: beat by 61.5%
Price chart
- 1 day+2.7%
- 1 week+1.5%
- 1 month-18.5%
- This year-76.6%
- 1 year-87.9%
- 5 years-99.9%
- S&P 500 this year+11.2%
Loading chart…
Third-party market data · may be delayed
At a glance
Profitability
- Revenue (TTM)
- $17,000
- Operating margin
- -30129.4%
- Net margin
- -29541.2%
- EPS (TTM, diluted)
- $-7.75
Growth
- Share count change
- +368.7%
Cash
- Free cash flow (TTM)
- -$4M
- FCF margin
- -23276.5%
- Stock pay % of revenue
- 2629.4%
News & updates
Company announcements, filed results and changes that matter to shareholders.
No recent updates are available for PRFX from the sources we follow. See filings →
Valuation models
We value PRF Technologies Ltd. as an operating company, with every model that fits that kind of business. Cost of equity 11.7%: the 10-year Treasury yield (4.9%) plus a beta of 1.5 times a 4.5% equity risk premium.
| Model | Value per share | In the combined value? |
|---|---|---|
| Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. | — | Does not apply: no positive earnings in the latest twelve months |
| Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. | — | Does not apply: the model gives no positive value |
| Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. | — | Does not apply: return on equity is not positive |
| Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. | — | Does not apply: revenue and margins don't support a positive value |
| Price-to-sales vs peers Sales per share times peers' typical price-to-sales; used only when earnings are negative. | — 0 | Does not apply: no positive value |
| Combined value Weighted average of the models that apply: the primary model (price-to-earnings vs peers) counts double. Models more than 5x or less than 0.2x the share price, or more than 3x away from the other models' median, are left out. | — | No model applies: the filings don’t yet support a value. |
Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare PRF Technologies Ltd. with Pharmaceuticals in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.
Valuation multiples over time Market data may be delayed
| At fiscal year end | 2023 | 2024 | 2025 |
|---|---|---|---|
| Share price | $82.50 | $16.77 | $3.21 |
| Market value | $6m | $2m | $2m |
| + Net debt (− = net cash) | −$8m | −$4m | −$3m |
| Enterprise value | −$2m | −$2m | −$1m |
| Multiples | |||
| Price / sales | — | — | 122.4x |
| Price / earnings | — | — | — |
| Price / free cash flow | — | — | — |
| EV / EBITDA | — | — | — |
Moat
Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.
Forecasts and guidance
Analysts' consensus
No analyst estimates are published for PRF Technologies Ltd.: too few analysts cover it.
Earnings against estimates
| Quarter to | Estimate | Actual | Surprise |
|---|---|---|---|
| Jun 2024 | −$124.80 | −$48.00 | +61.5% |
| Mar 2024 | −$288.00 | −$326.40 | −13.3% |
Adjusted EPS as companies report it, against the average analyst estimate.
Positioning
- Short interest
- 0.6% of tradable shares
- Days to cover
- 0.06 at average volume
- Short interest, 1 month
- −71% to October 15, 2026
- Held by institutions
- 7% of shares
- Held by insiders
- 6.6% of shares
- Employees
- 6 full time
Share-price performance
Market data may be delayedReturn and risk by year
| Calendar year | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 to date |
|---|---|---|---|---|---|---|
| Return | ||||||
| PRFX | −70% | −69% | −33% | −80% | −81% | −77% |
| Industry peers (median) | −18% | −49% | −13% | −2% | +9% | −12% |
| S&P 500 | +29% | −18% | +26% | +25% | +18% | +11% |
| Months that ended higher | ||||||
| PRFX | 33% | 25% | 58% | 17% | 25% | 27% |
| S&P 500 | 75% | 42% | 67% | 75% | 75% | 46% |
| Largest fall from a high during the year | ||||||
| PRFX | −82% | −77% | −89% | −97% | −83% | −87% |
| S&P 500 | −5% | −25% | −10% | −8% | −19% | −9% |
Worst fall since September 1, 2020: 100% from February 22, 2021 to October 19, 2026. Getting back needed a 287260% gain, and the shares have not yet recovered.
Price behaviour
- 52-week range
- $0.71 – $5.80
- From 52-week high
- −87.1%
- vs 50-day average
- −15.8%
- vs 200-day average
- −58.6%
- Volatility (1 year)
- 179%
- Beta vs S&P 500
- 2.75
Fundamentals
Financial statements
| Fiscal year | 2023 Dec 2023 | 2024 Dec 2024 | 2025 Dec 2025 |
|---|---|---|---|
| Income | |||
| Revenue | 0 | 0 | 0 |
| Gross profit | 0 | 0 | −0 |
| EBITDA | −10 | −15 | −5 |
| Operating income | −10 | −15 | −5 |
| Net income | −9 | −15 | −5 |
| Diluted EPS | −$122.94 | −$105.52 | −$7.47 |
| Margins | |||
| Gross margin | — | — | −311.8% |
| EBITDA margin | — | — | <−999% |
| Operating margin | — | — | <−999% |
| Net margin | — | — | <−999% |
| Free-cash-flow margin | — | — | <−999% |
| Cash flow | |||
| Cash from operations | −7 | −13 | −4 |
| Capital spending | 0 | 0 | 0 |
| Free cash flow | −7 | −13 | −4 |
| Stock-based pay | 1 | 0 | 0 |
| Free cash flow after stock pay | −7 | −13 | −4 |
| Balance sheet | |||
| Cash | 8 | 4 | 3 |
| Total debt | 0 | 0 | 0 |
| Net debt (negative = net cash) | −8 | −4 | −3 |
| Diluted shares | — | — | — |
Financial health
- Short-term assets cover short-term liabilities $4m of assets due within a year against $2m of liabilities due within a year.
- Short-term assets cover long-term liabilities $4m short-term assets against $267,000 of longer-dated liabilities.
- More cash than debt Cash or debt not separately reported. Not assessable.
- Debt below 40% of shareholders' equity Equity or debt not reported. Not assessable.
- Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
- A year's operating cash flow covers at least 20% of debt Cash flow or debt not reported. Not assessable.
- Operating profit covers interest at least five times over Interest not separately reported. Not assessable.
Dividends, buybacks and capital spending
- Diluted share count
- +368.7%
- year over year
- R&D spending
- 6682.4%
- of revenue
- Sales & admin spending
- 8247.1%
- of revenue
Competitors: side by side with peers
| Last 12 months unless stated | PRFX | AKAN | TLPH | SCNX | SXTP | SXTC | Median |
|---|---|---|---|---|---|---|---|
| Revenue, last 12 months | $17000 | $258075 | $1000 | $821315 | $1m | $1m | $276m |
| Revenue growth, last 12 months | — | −69.2% | −96.3% | 540.6% | 73.2% | −34.6% | 9.9% |
| Revenue growth, 3-year average | — | — | −92.4% | −58.5% | 74.9% | — | 5.5% |
| Revenue growth, latest quarter | — | — | −100.0% | 449.1% | 106.0% | — | 6.5% |
| Gross margin | −311.8% | −60.5% | −486.2% | 87.7% | 19.4% | 21.9% | 62.0% |
| Operating margin | <−999% | <−999% | <−999% | <−999% | −774.9% | −625.9% | −5.9% |
| Operating margin, 3-year average | — | — | <−999% | <−999% | <−999% | −267.4% | −7.4% |
| Net margin | <−999% | −467.1% | <−999% | <−999% | −729.9% | −545.2% | −7.3% |
| Cash from operations / revenue | <−999% | <−999% | <−999% | <−999% | −789.8% | −353.0% | 10.2% |
| Free-cash-flow margin | <−999% | <−999% | <−999% | <−999% | −800.6% | −353.0% | 8.6% |
| Free-cash-flow margin, 3-year average | — | — | <−999% | <−999% | — | −126.6% | 7.4% |
| Stock pay / revenue | >999% | 21.3% | >999% | 257.1% | 37.2% | 466.2% | 3.6% |
| Change in share count | 368.7% | −93.4% | 34.4% | 2.1% | — | >999% | 1.9% |
Peer comparison
| Measure | Company | Peer median | Rank |
|---|---|---|---|
| Gross margin Profitability | -311.8% | 59.8% | 59 of 59 |
| Operating margin Profitability | -30129.4% | -5.9% | 66 of 67 |
| Net margin Profitability | -29541.2% | -7.3% | 74 of 75 |
| Free-cash-flow margin Cash generation | -23276.5% | 10.1% | 73 of 74 |
| Stock pay as % of revenue Cash generation | 2629.4% | 3.6% | 68 of 69 |
| Change in share count Balance sheet | 368.7% | 1.5% | 60 of 62 |
Rank 1 = best in the group (for spending, debt and dilution, lower ranks first).
Who owns it
- Reported value
- $280,557
- Institutions reporting
- 7
- Shares held vs prior quarter
- ▲ 1191.6%
| Manager | Value | Shares | Share of 13F value | Shares QoQ |
|---|---|---|---|---|
| Yorkville Advisors Global, LP | $111,922 | 81K | 39.9% | New |
| Jane Street Group, LLC | $110,934 | 80K | 39.5% | New |
| Citadel Advisors LLC | $39,434 | 29K | 14.1% | ▲ 116.1% |
| UBS Group AG | $14,373 | 10K | 5.1% | ▲ 1098.5% |
| Morgan Stanley | $3,840 | 3K | 1.4% | ▲ 72.7% |
| Osaic Holdings, Inc. | $53 | 0K | 0.0% | 0.0% |
| Rockefeller Capital Management L.P. | $1 | 0K | 0.0% | New |
From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not PRF Technologies Ltd.'s complete shareholder register. Values are as reported by the filers .
Insider trading activity
Full insider history and chartFrom insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.
Earnings dates and SEC filings
Data status
| Data | Last updated | Source |
|---|---|---|
| Share price | Exchange closing prices | |
| News and updates | Company releases and SEC 8-K filings | |
| Analyst estimates | Aggregated analyst estimates | |
| Valuation and scores | Our models, from the filed figures |
PRF Technologies Ltd. in brief
- What does PRF Technologies Ltd. do?
- PRF Technologies Ltd. is a US-listed company in the pharmaceuticals industry. Its financial year ends in December.
- What is PRF Technologies Ltd.'s stock ticker?
- PRF Technologies Ltd. trades under the ticker PRFX on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
- What is PRF Technologies Ltd.'s free cash flow?
- PRF Technologies Ltd.'s free-cash-flow margin is -23276.5% of revenue over the trailing twelve months, ranking 73 of the 74 pharmaceuticals companies we cover.
- Who are PRF Technologies Ltd.'s largest institutional shareholders?
- By value reported in 13F filings for June 30, 2026, the largest reported holders are Yorkville Advisors Global, LP, Jane Street Group, LLC and Citadel Advisors LLC. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
- What is PRF Technologies Ltd.'s market cap?
- On December 31, 2025, PRF Technologies Ltd.'s market capitalisation was about $2.1M and net debt of -$3.1M. Market figures come from third-party market data and may be delayed.
- Who are PRF Technologies Ltd.'s competitors?
- In our Pharmaceuticals peer group, the companies closest to PRF Technologies Ltd. are Akanda Corp., Talphera, Inc., Scienture Holdings, Inc., 60 Degrees Pharmaceuticals, Inc. and China SXT Pharmaceuticals, Inc. The side-by-side comparison below sets their revenue, margins and growth against PRF Technologies Ltd.'s.
Follow research on PRF Technologies Ltd.
New research on the companies we cover arrives in the weekly email. Free, one email a week.